US4873088A
(en)
*
|
1983-09-06 |
1989-10-10 |
Liposome Technology, Inc. |
Liposome drug delivery method and composition
|
JPS6058915A
(ja)
*
|
1983-09-12 |
1985-04-05 |
Fujisawa Pharmaceut Co Ltd |
薬物含有脂質小胞体製剤
|
EP0152379A3
(de)
*
|
1984-02-15 |
1986-10-29 |
Ciba-Geigy Ag |
Verfahren zur Herstellung von pharmazeutischen Zusammensetzungen enthaltend unilamellare Liposomen
|
FR2562421B1
(fr)
*
|
1984-04-09 |
1989-02-17 |
Sandoz Sa |
Perfectionnements a la therapie par l'interleukine
|
US5283122A
(en)
*
|
1984-04-19 |
1994-02-01 |
University Of Tennessee Research Corporation |
Fused liposome and acid induced method for liposome fusion
|
CA1260393A
(en)
*
|
1984-10-16 |
1989-09-26 |
Lajos Tarcsay |
Liposomes of synthetic lipids
|
US4921706A
(en)
*
|
1984-11-20 |
1990-05-01 |
Massachusetts Institute Of Technology |
Unilamellar lipid vesicles and method for their formation
|
EP0208764A4
(en)
*
|
1985-01-11 |
1987-10-08 |
Univ California |
PRESERVATION PROCEDURE FOR LIPOSOME.
|
US4740375A
(en)
*
|
1985-02-25 |
1988-04-26 |
Technology Unlimited, Inc. |
Gelcores
|
US4736051A
(en)
*
|
1985-03-20 |
1988-04-05 |
Kao Corporation |
Process for the preparation of an alkali metal salt of a diester phosphoric acid
|
US5622713A
(en)
*
|
1985-09-17 |
1997-04-22 |
The Regents Of The University Of California |
Method of detoxifying animal suffering from overdose
|
IE58981B1
(en)
*
|
1985-10-15 |
1993-12-15 |
Vestar Inc |
Anthracycline antineoplastic agents encapsulated in phospholipid micellular particles
|
MY101125A
(en)
*
|
1985-12-23 |
1991-07-31 |
Kao Corp |
Gel-like emulsion and o/w emulsions obtained from gel-like emulsion
|
US4923854A
(en)
*
|
1986-01-22 |
1990-05-08 |
The Liposome Company, Inc. |
Solubilization of hydrophobic materials using lysophospholipid
|
US4888288A
(en)
*
|
1986-01-30 |
1989-12-19 |
Becton Dickinson And Company |
Vesicles resistant to enzyme lysis and use thereof in an enzyme assay
|
JP2760355B2
(ja)
*
|
1986-06-16 |
1998-05-28 |
ザ リポソーム カンパニー,インコーポレイテッド |
不均整誘導リポソーム
|
US5204112A
(en)
*
|
1986-06-16 |
1993-04-20 |
The Liposome Company, Inc. |
Induction of asymmetry in vesicles
|
US5252263A
(en)
*
|
1986-06-16 |
1993-10-12 |
The Liposome Company, Inc. |
Induction of asymmetry in vesicles
|
JPS63182029A
(ja)
*
|
1987-01-22 |
1988-07-27 |
Agency Of Ind Science & Technol |
リポソ−ム
|
US5154930A
(en)
*
|
1987-03-05 |
1992-10-13 |
The Liposome Company, Inc. |
Pharmacological agent-lipid solution preparation
|
US4963297A
(en)
*
|
1987-12-22 |
1990-10-16 |
The Liposome Company, Inc. |
Spontaneous vesticulation of multilamellar liposomes
|
CA1338702C
(en)
*
|
1987-03-05 |
1996-11-12 |
Lawrence D. Mayer |
High drug:lipid formulations of liposomal- antineoplastic agents
|
MX9203808A
(es)
*
|
1987-03-05 |
1992-07-01 |
Liposome Co Inc |
Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
|
CA1323306C
(en)
*
|
1987-03-05 |
1993-10-19 |
Mircea C. Popescu |
Pharmacological agent-lipid solution preparation
|
FR2616328B1
(fr)
*
|
1987-06-12 |
1990-03-02 |
Moet Hennessy Rech |
Composition a base de phases lamellaires lipidiques hydratees ou de liposomes contenant un extrait de murier, ou au moins une flavone, en particulier une kuwanone et composition pharmaceutique, notamment dermatologique, a activite depigmentante, ou anti-inflammatoire, ou cosmetique, l'incorporant
|
AU618972B2
(en)
*
|
1987-10-06 |
1992-01-16 |
Houston Biotechnology Incorporated |
Phosphatidyl treatment of viral disease
|
US4946683A
(en)
*
|
1987-11-18 |
1990-08-07 |
Vestar, Inc. |
Multiple step entrapment/loading procedure for preparing lipophilic drug-containing liposomes
|
CA1330199C
(en)
*
|
1987-12-22 |
1994-06-14 |
Thomas D. Madden |
Spontaneous vesiculation of multilamellar liposomes
|
US5133965A
(en)
*
|
1988-06-08 |
1992-07-28 |
Fountain Pharmaceuticals, Inc. |
Dressing material having adsorbed thereon a solvent dilution microcarrier precursor solution
|
US5269979A
(en)
*
|
1988-06-08 |
1993-12-14 |
Fountain Pharmaceuticals, Inc. |
Method for making solvent dilution microcarriers
|
FR2638639A1
(fr)
*
|
1988-11-08 |
1990-05-11 |
Parincos Parfumerie Cosmet Int |
Composition et procede d'obtention de liposomes oligolamellaires en vue d'une application en cosmetologie et dermatologie topique
|
US5153000A
(en)
*
|
1988-11-22 |
1992-10-06 |
Kao Corporation |
Phosphate, liposome comprising the phosphate as membrane constituent, and cosmetic and liposome preparation comprising the liposome
|
US5139803A
(en)
*
|
1989-02-09 |
1992-08-18 |
Nabisco, Inc. |
Method and liposome composition for the stabilization of oxidizable substances
|
US5015483A
(en)
*
|
1989-02-09 |
1991-05-14 |
Nabisco Brands, Inc. |
Liposome composition for the stabilization of oxidizable substances
|
US4994440A
(en)
*
|
1989-02-13 |
1991-02-19 |
Creaven Patrick J |
Method for the treatment of renal cell carcinoma
|
US5116964A
(en)
|
1989-02-23 |
1992-05-26 |
Genentech, Inc. |
Hybrid immunoglobulins
|
WO1990012565A1
(en)
*
|
1989-04-25 |
1990-11-01 |
Nattermann, A. & Cie. Gmbh |
Water-containing formulations with phospholipids
|
DE3919982A1
(de)
*
|
1989-06-19 |
1990-12-20 |
Liedtke Pharmed Gmbh |
Orale lipidarzneiform
|
US5290563A
(en)
*
|
1989-07-27 |
1994-03-01 |
Laboratoire Des Stallergenes |
Method for combining a mixture of heterogeneous substances with liposomes
|
GB8918879D0
(en)
*
|
1989-08-18 |
1989-09-27 |
Danbiosyst Uk |
Pharmaceutical compositions
|
DE4005711C1
(fi)
*
|
1990-02-23 |
1991-06-13 |
A. Nattermann & Cie Gmbh, 5000 Koeln, De |
|
DE4013632A1
(de)
*
|
1990-04-27 |
1991-10-31 |
Max Planck Gesellschaft |
Liposomen mit positiver ueberschussladung
|
US5165994A
(en)
*
|
1990-06-05 |
1992-11-24 |
University Of Delaware |
Spontaneous equilbrium surfactant vesicles
|
DE4018767A1
(de)
*
|
1990-06-12 |
1991-12-19 |
Braun Melsungen Ag |
Wirkstofffreie liposomen zur behandlung von atherosklerose
|
EP0467838A3
(en)
*
|
1990-07-17 |
1992-09-02 |
Ciba-Geigy Ag |
Process for preparing an injectable liposome dispersion
|
CA2046830C
(en)
|
1990-07-19 |
1999-12-14 |
Patrick P. Deluca |
Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
|
FR2674128A1
(fr)
*
|
1991-03-19 |
1992-09-25 |
Patrinove |
"vecteurs de structure capsulaire" et leurs applications dans le transport de substances ou principes actifs.
|
US6764693B1
(en)
|
1992-12-11 |
2004-07-20 |
Amaox, Ltd. |
Free radical quenching composition and a method to increase intracellular and/or extracellular antioxidants
|
US5720973A
(en)
*
|
1993-02-18 |
1998-02-24 |
Knoll Aktiengesellschaft |
Preparation of colloidal aqueous solutions of active substances of low solubility and a lipid therefor
|
GB9320668D0
(en)
*
|
1993-10-07 |
1993-11-24 |
Secr Defence |
Liposomes containing particulare materials
|
US5840328A
(en)
*
|
1994-01-11 |
1998-11-24 |
The Liposome Company, Inc. |
Treatment using arachidonic acid metabolite and particulate formulations
|
US5877016A
(en)
|
1994-03-18 |
1999-03-02 |
Genentech, Inc. |
Human trk receptors and neurotrophic factor inhibitors
|
US5708142A
(en)
|
1994-05-27 |
1998-01-13 |
Genentech, Inc. |
Tumor necrosis factor receptor-associated factors
|
DE4423131A1
(de)
*
|
1994-07-01 |
1996-01-04 |
Bayer Ag |
Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
|
IT1270678B
(it)
*
|
1994-10-20 |
1997-05-07 |
Bayer Ag |
Liposomi al chetoprofen
|
US6093697A
(en)
*
|
1994-11-07 |
2000-07-25 |
The University Of Virginia Patent Foundation |
Synthetic insulin mimetic substances
|
US20020048596A1
(en)
*
|
1994-12-30 |
2002-04-25 |
Gregor Cevc |
Preparation for the transport of an active substance across barriers
|
US7517858B1
(en)
*
|
1995-06-07 |
2009-04-14 |
The Regents Of The University Of California |
Prodrugs of pharmaceuticals with improved bioavailability
|
US20040208922A1
(en)
*
|
1995-06-07 |
2004-10-21 |
The Regents Of The University Of California |
Method for loading lipid like vesicles with drugs or other chemicals
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
US6183774B1
(en)
|
1996-01-31 |
2001-02-06 |
Collaborative Laboratories, Inc. |
Stabilizing vitamin A derivatives by encapsulation in lipid vesicles formed with alkylammonium fatty acid salts
|
US5874105A
(en)
*
|
1996-01-31 |
1999-02-23 |
Collaborative Laboratories, Inc. |
Lipid vesicles formed with alkylammonium fatty acid salts
|
US6071535A
(en)
*
|
1996-01-31 |
2000-06-06 |
Collaborative Laboratories, Inc. |
Lipid vesicles formed with alkylammonium fatty acid salts
|
US6723531B2
(en)
*
|
1996-04-05 |
2004-04-20 |
The Salk Institute For Biological Studies |
Method for modulating expression of exogenous genes in mammalian systems, and products related thereto
|
US5766877A
(en)
*
|
1996-05-10 |
1998-06-16 |
Amgen Inc. |
Genes encoding art, an agouti-related transcript
|
PT939804E
(pt)
|
1996-10-25 |
2005-11-30 |
Human Genome Sciences Inc |
Neutroquina alfa
|
US6593290B1
(en)
|
1996-11-01 |
2003-07-15 |
Genentech, Inc. |
Treatment of inner ear hair cells
|
US6156728A
(en)
|
1996-11-01 |
2000-12-05 |
Genentech, Inc. |
Treatment of inner ear hair cells
|
US7390891B1
(en)
|
1996-11-15 |
2008-06-24 |
Amgen Inc. |
Polynucleotides encoding a telomerase component TP2
|
US5919656A
(en)
*
|
1996-11-15 |
1999-07-06 |
Amgen Canada Inc. |
Genes encoding telomerase protein 1
|
US5935572A
(en)
*
|
1997-01-10 |
1999-08-10 |
Collaborative Laboratories, Inc. |
Composition containing protease separate from glycosidase for removing nits in treating lice infestation
|
US5827532A
(en)
*
|
1997-01-31 |
1998-10-27 |
The Reagents Of The University Of California |
Method for loading lipsomes with ionizable phosphorylated hydrophobic compounds, pharmaceutical preparations and a method for administering the preparations
|
US6103706A
(en)
*
|
1997-04-29 |
2000-08-15 |
New York Blood Center, Inc. |
Methods for treating viral infections
|
EP2332975A1
(en)
|
1997-05-30 |
2011-06-15 |
Human Genome Sciences, Inc. |
Human proteins
|
US6663899B2
(en)
|
1997-06-13 |
2003-12-16 |
Genentech, Inc. |
Controlled release microencapsulated NGF formulation
|
US6113947A
(en)
*
|
1997-06-13 |
2000-09-05 |
Genentech, Inc. |
Controlled release microencapsulated NGF formulation
|
US6300488B1
(en)
|
1997-07-10 |
2001-10-09 |
The Salk Institute For Biological Studies |
Modified lepidopteran receptors and hybrid multifunctional proteins for use in transcription and regulation of transgene expression
|
US6342220B1
(en)
|
1997-08-25 |
2002-01-29 |
Genentech, Inc. |
Agonist antibodies
|
WO1999011242A1
(en)
*
|
1997-09-04 |
1999-03-11 |
Biozone Laboratories, Inc. |
Oral liposomal delivery system
|
US6165997A
(en)
*
|
1997-11-20 |
2000-12-26 |
Statens Serum Institut |
Phospholipids having antimicrobial activity with or without the presence of antimicrobials
|
ATE472599T1
(de)
*
|
1997-11-21 |
2010-07-15 |
Human Genome Sciences Inc |
Chemokin alpha-5
|
US5906979A
(en)
*
|
1998-01-27 |
1999-05-25 |
Insmed Pharmaceuticals, Inc. |
Compositions and methods for treating metabolic diseases characterized by hyperandrogenism and/or anovulation and/or infertility
|
AU2581599A
(en)
|
1998-02-04 |
1999-08-23 |
Genentech Inc. |
Use of heregulin as an epithelial cell growth factor
|
NZ525914A
(en)
|
1998-03-10 |
2004-03-26 |
Genentech Inc |
Novel polypeptides and nucleic acids encoding the same
|
DE69939374D1
(de)
|
1998-03-17 |
2008-10-02 |
Genentech Inc |
Zu vegf und bmp1 homologe polypeptide
|
US6949528B1
(en)
*
|
1998-03-18 |
2005-09-27 |
Goddard John G |
Compositions containing lysophosphatidic acids which inhibit apoptosis and uses thereof
|
DE69943022D1
(de)
|
1998-03-19 |
2011-01-20 |
Human Genome Sciences Rockville |
Der gemeinsamen gamma-kette ähnlicher zytokinrezeptor
|
US6333318B1
(en)
|
1998-05-14 |
2001-12-25 |
The Salk Institute For Biological Studies |
Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto
|
US5973119A
(en)
*
|
1998-06-05 |
1999-10-26 |
Amgen Inc. |
Cyclin E genes and proteins
|
US6344541B1
(en)
|
1998-09-25 |
2002-02-05 |
Amgen Inc. |
DKR polypeptides
|
AUPP785098A0
(en)
|
1998-12-21 |
1999-01-21 |
Victor Chang Cardiac Research Institute, The |
Treatment of heart disease
|
DE69825495T2
(de)
*
|
1998-12-23 |
2005-07-28 |
Idea Ag |
Verbesserte formulierung zur topischen, nichtinvasiven anwendung in vivo
|
ATE216223T1
(de)
|
1999-01-27 |
2002-05-15 |
Idea Ag |
Transnasaler transport bzw. impfung mit hochadaptierbaren trägern
|
ATE216875T1
(de)
|
1999-01-27 |
2002-05-15 |
Idea Ag |
Nichtinvasive impfung durch die haut
|
US6303749B1
(en)
|
1999-01-29 |
2001-10-16 |
Amgen Inc. |
Agouti and agouti-related peptide analogs
|
US7708993B2
(en)
|
1999-02-03 |
2010-05-04 |
Amgen Inc. |
Polypeptides involved in immune response
|
KR20010101987A
(ko)
|
1999-02-03 |
2001-11-15 |
스티븐 엠. 오드레 |
면역 반응과 관련된 신규한 폴리펩티드
|
US7435796B1
(en)
|
1999-02-03 |
2008-10-14 |
Amgen Inc. |
Antibodies which bind B7RP1
|
US8624010B1
(en)
|
1999-02-03 |
2014-01-07 |
Steven K. Yoshinaga |
Nucleic acids encoding B7RP1
|
AU3501700A
(en)
|
1999-02-26 |
2000-09-14 |
Human Genome Sciences, Inc. |
Human endokine alpha and methods of use
|
WO2000058479A1
(en)
|
1999-03-26 |
2000-10-05 |
Amgen Inc. |
Beta secretase genes and polypeptides
|
US6635249B1
(en)
|
1999-04-23 |
2003-10-21 |
Cenes Pharmaceuticals, Inc. |
Methods for treating congestive heart failure
|
WO2001001962A1
(en)
|
1999-07-05 |
2001-01-11 |
Idea Ag. |
A method for the improvement of transport across adaptable semi-permeable barriers
|
US7408047B1
(en)
|
1999-09-07 |
2008-08-05 |
Amgen Inc. |
Fibroblast growth factor-like polypeptides
|
US7459540B1
(en)
|
1999-09-07 |
2008-12-02 |
Amgen Inc. |
Fibroblast growth factor-like polypeptides
|
US7057015B1
(en)
|
1999-10-20 |
2006-06-06 |
The Salk Institute For Biological Studies |
Hormone receptor functional dimers and methods of their use
|
US6372722B1
(en)
|
2000-01-19 |
2002-04-16 |
Genteric, Inc. |
Method for nucleic acid transfection of cells
|
US20030103978A1
(en)
|
2000-02-23 |
2003-06-05 |
Amgen Inc. |
Selective binding agents of osteoprotegerin binding protein
|
US7514239B2
(en)
|
2000-03-28 |
2009-04-07 |
Amgen Inc. |
Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
|
JP2003530838A
(ja)
|
2000-04-12 |
2003-10-21 |
ヒューマン ゲノム サイエンシズ インコーポレイテッド |
アルブミン融合タンパク質
|
EP1294949A4
(en)
|
2000-06-15 |
2004-08-25 |
Human Genome Sciences Inc |
HUMAN TUMORNESCROSE FACTOR DELTA AND EPSILON
|
EP2275549A1
(en)
|
2000-06-23 |
2011-01-19 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
CA2648051A1
(en)
|
2000-06-23 |
2002-01-03 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
MXPA02012747A
(es)
|
2000-06-28 |
2003-09-25 |
Amgen Inc |
Moleculas del receptor de linfopoietina estromica timica y sus usos.
|
US6989247B2
(en)
|
2000-11-28 |
2006-01-24 |
Celltech R & D, Inc. |
Compositions and methods for diagnosing or treating psoriasis
|
AU2002217969B2
(en)
|
2000-11-28 |
2007-12-20 |
Amgen Canada Inc. |
Polypeptides involved in immune response
|
US7087726B2
(en)
|
2001-02-22 |
2006-08-08 |
Genentech, Inc. |
Anti-interferon-α antibodies
|
GB0111628D0
(en)
|
2001-05-11 |
2001-07-04 |
Scancell Ltd |
Binding member
|
AUPR546801A0
(en)
|
2001-06-05 |
2001-06-28 |
Commonwealth Scientific And Industrial Research Organisation |
Recombinant antibodies
|
EP1414517A4
(en)
*
|
2001-06-26 |
2008-02-06 |
Photomed Technologies Inc |
MULTIPLE WAVELENGTH ILLUMINATOR
|
JP4212470B2
(ja)
|
2001-06-26 |
2009-01-21 |
アムジェン フレモント インク. |
Opglへの抗体
|
JP4399260B2
(ja)
|
2001-08-24 |
2010-01-13 |
ニューレン ファーマシューティカルズ リミテッド |
神経再生ペプチドおよび脳損傷治療におけるその使用方法
|
DK1427830T3
(da)
|
2001-08-29 |
2012-07-23 |
Genentech Inc |
Bv8-nukleinsyrer og -polypeptider med mitogen aktivitet
|
GB0121709D0
(en)
*
|
2001-09-07 |
2001-10-31 |
Imp College Innovations Ltd |
Food inhibition agent
|
IL160983A0
(en)
|
2001-09-24 |
2004-08-31 |
Imp College Innovations Ltd |
Use of pyy for preparation of a medicament for modification of feeding behavior
|
EP1930420A1
(en)
|
2001-09-26 |
2008-06-11 |
Merck & Co., Inc. |
Isolated nucleic acid molecules encoding a bacterial uracil phosphoribosyl-transferase enzyme, cells transformed therewith and uses thereof
|
CA2461998A1
(en)
*
|
2001-09-26 |
2003-04-10 |
Merck & Co., Inc. |
Isolated nucleic acid molecules encoding a bacterial uracil transport protein and a bacterial uracil phosphoribosyl-transferase enzyme, cells transformed therewith and uses thereof
|
DE10148066A1
(de)
*
|
2001-09-28 |
2003-04-24 |
Max Planck Gesellschaft |
Liposome enthaltend (Ether)-Lysolecithine
|
DE10148067A1
(de)
*
|
2001-09-28 |
2003-04-17 |
Max Planck Gesellschaft |
Hitzesterilisierbare Alkylphosphocholin-Liposome
|
US7138370B2
(en)
|
2001-10-11 |
2006-11-21 |
Amgen Inc. |
Specific binding agents of human angiopoietin-2
|
US7521053B2
(en)
|
2001-10-11 |
2009-04-21 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
US20030077282A1
(en)
|
2001-10-12 |
2003-04-24 |
Bigler Michael Eric |
Use of bispecific antibodies to regulate immune responses
|
US20040106773A1
(en)
*
|
2001-10-12 |
2004-06-03 |
Hao Wang |
Human tuberoinfundibular peptide of 39 residues
|
CA2471363C
(en)
|
2001-12-21 |
2014-02-11 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US8058233B2
(en)
*
|
2002-01-10 |
2011-11-15 |
Oregon Health And Science University |
Modification of feeding behavior using PYY and GLP-1
|
AU2003201998C1
(en)
|
2002-01-10 |
2012-10-25 |
Imperial Innovations Limited |
Modification of feeding behavior
|
US7662924B2
(en)
|
2002-02-22 |
2010-02-16 |
The Board Of Trustees Of The University Of Illinois |
Beta chain-associated regulator of apoptosis
|
US20030180348A1
(en)
*
|
2002-03-22 |
2003-09-25 |
Levinson R. Saul |
Transcellular drug delivery system
|
JP4761710B2
(ja)
|
2002-04-05 |
2011-08-31 |
アムジェン インコーポレイテッド |
選択的opgl経路インヒビターとしてのヒト抗opgl中和抗体
|
WO2003099320A1
(en)
|
2002-05-24 |
2003-12-04 |
Zensun (Shanghai) Sci-Tech.Ltd |
Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
|
EP2305710A3
(en)
|
2002-06-03 |
2013-05-29 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
ATE549033T1
(de)
|
2002-09-06 |
2012-03-15 |
Amgen Inc |
Therapeutischer menschlicher monoklonaler anti-il-1r1-antikörper
|
KR100489701B1
(ko)
*
|
2002-10-09 |
2005-05-16 |
주식회사 태평양 |
고농도의 트리터페노이드를 함유하는 미소화 리포좀 및 그제조방법
|
US7473432B2
(en)
*
|
2002-10-11 |
2009-01-06 |
Idea Ag |
NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
|
AU2003285874A1
(en)
|
2002-10-16 |
2004-05-04 |
Amgen Inc. |
HUMAN ANTI-IFN-Gamma NEUTRALIZING ANTIBODIES AS SELECTIVE IFN-Gamma PATHWAY INHIBITORS
|
JP4754219B2
(ja)
|
2002-12-02 |
2011-08-24 |
アムジエン・フレモント・インコーポレイテツド |
腫瘍壊死因子を対象とする抗体、およびそれらの使用
|
CA2511823A1
(en)
*
|
2002-12-30 |
2004-07-22 |
Amgen Inc. |
Combination therapy with co-stimulatory factors
|
GB0300571D0
(en)
*
|
2003-01-10 |
2003-02-12 |
Imp College Innovations Ltd |
Modification of feeding behaviour
|
KR101294959B1
(ko)
|
2003-03-12 |
2013-08-09 |
제넨테크, 인크. |
조혈을 촉진하기 위한 bv8 및(또는) eg-vegf의 용도
|
US8067544B2
(en)
|
2003-03-19 |
2011-11-29 |
Curagen Corporation |
Antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen and uses thereof
|
US7291590B2
(en)
|
2003-06-12 |
2007-11-06 |
Queen's University At Kingston |
Compositions and methods for treating atherosclerosis
|
CN102675462A
(zh)
|
2003-06-27 |
2012-09-19 |
艾默根佛蒙特有限公司 |
针对表皮生长因子受体的缺失突变体的抗体及其使用
|
CN103880955A
(zh)
|
2003-07-18 |
2014-06-25 |
安姆根有限公司 |
肝细胞生长因子的特异性结合物
|
ATE536186T1
(de)
|
2003-09-12 |
2011-12-15 |
Tercica Inc |
Verfahren zur behandlung von igf-1 (insulin-like growth factor 1)-mangel
|
EP1684791A4
(en)
|
2003-10-27 |
2009-07-01 |
Amgen Inc |
COMPOSITIONS AND METHODS FOR MODULATION OF IMMUNE REACTION TO AN IMMUNOGENIC THERAPEUTIC AGENT
|
JP2007530015A
(ja)
*
|
2004-01-05 |
2007-11-01 |
バイオテック・スタジオ・リミテッド・ライアビリティ・カンパニー |
生物治療学的、診断および研究試薬
|
JP4889505B2
(ja)
|
2004-02-02 |
2012-03-07 |
アンブレツクス・インコーポレイテツド |
被修飾されたヒト成長ホルモンポリペプチドおよびこれらの使用
|
EP1726647B1
(en)
|
2004-03-19 |
2015-01-07 |
GenomIdea, Inc. |
Gene promoting vascular endothelial cell growth
|
CA2564989C
(en)
|
2004-03-19 |
2014-05-27 |
Amgen, Inc. |
Reducing the risk of human and anti-human antibodies through v gene manipulation
|
WO2005094879A2
(en)
*
|
2004-03-23 |
2005-10-13 |
Amgen, Inc. |
Monoclonal antibodies specific for human ox40l (cd 134l)
|
CA2560618A1
(en)
*
|
2004-04-02 |
2005-10-13 |
Queen's University At Kingston |
A cell culture system for modelling serum amyloid a amyloidogenesis and identifying amyloid modulating compounds
|
GB0410627D0
(en)
|
2004-05-12 |
2004-06-16 |
Scancell Ltd |
Specific binding members
|
EP1598428A1
(en)
|
2004-05-18 |
2005-11-23 |
Georg Dewald |
Methods and kits to detect Hereditary angioedema type III
|
JP2008503217A
(ja)
|
2004-06-18 |
2008-02-07 |
アンブレツクス・インコーポレイテツド |
新規抗原結合ポリペプチド及びそれらの使用
|
JP4852539B2
(ja)
|
2004-06-22 |
2012-01-11 |
ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ |
腫瘍細胞増殖をFOXM1siRNAによって阻害する方法
|
ME00226B
(me)
|
2004-07-15 |
2011-02-10 |
Medarex Llc |
Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
|
WO2009100255A2
(en)
|
2008-02-08 |
2009-08-13 |
Ambrx, Inc. |
Modified leptin polypeptides and their uses
|
CA2569381A1
(en)
|
2004-07-21 |
2006-08-31 |
Ambrx, Inc. |
Biosynthetic polypeptides utilizing non-naturally encoded amino acids
|
US7709611B2
(en)
|
2004-08-04 |
2010-05-04 |
Amgen Inc. |
Antibodies to Dkk-1
|
EP1786428B1
(en)
|
2004-08-17 |
2012-05-16 |
The Johns Hopkins University |
Pde5 inhibitor compositions and methods for treating cardiac indications
|
JP2008515813A
(ja)
|
2004-10-06 |
2008-05-15 |
アグリ−バイオテック ピーティーワイ リミテッド |
抗体産生方法
|
KR20070086045A
(ko)
*
|
2004-11-12 |
2007-08-27 |
이데아 아게 |
피부 상태 치료에서의 확대된 표면 집합체
|
EP1824886B1
(en)
|
2004-11-17 |
2010-12-22 |
Amgen Inc. |
Fully human monoclonal antibodies to il-13
|
TW200635946A
(en)
|
2004-12-20 |
2006-10-16 |
Abgenix Inc |
Binding proteins specific for human matriptase
|
KR101017301B1
(ko)
|
2004-12-21 |
2011-02-28 |
메드임뮨 리미티드 |
앤지오포이에틴-2에 대한 항체 및 그의 용도
|
KR20070090023A
(ko)
|
2004-12-22 |
2007-09-04 |
암브룩스, 인코포레이티드 |
변형 인간 성장 호르몬
|
WO2006069246A2
(en)
|
2004-12-22 |
2006-06-29 |
Ambrx, Inc. |
Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
|
KR101224781B1
(ko)
|
2004-12-22 |
2013-01-21 |
암브룩스, 인코포레이티드 |
비천연적으로 코딩된 아미노산을 포함하는 인간 성장호르몬의 조제물
|
WO2006068802A2
(en)
|
2004-12-22 |
2006-06-29 |
Ambrx, Inc. |
COMPOSITIONS OF AMINOACYL-tRNA SYNTHETASE AND USES THEREOF
|
JP2008525032A
(ja)
|
2004-12-22 |
2008-07-17 |
アンブレツクス・インコーポレイテツド |
組換えヒト成長ホルモンを発現及び精製するための方法
|
US20060154285A1
(en)
*
|
2004-12-29 |
2006-07-13 |
Robishaw Janet D |
Zebrafish heterotrimer G-protein gamma 2 subunit (GNG2)
|
ES2395953T3
(es)
|
2005-01-26 |
2013-02-18 |
Amgen Fremont Inc. |
Anticuerpos frente a interleucina-1 beta
|
EP2842559A3
(en)
*
|
2005-04-08 |
2015-03-18 |
Chimerix, Inc. |
Compounds, compositions and methods for the treatment of viral infections and other medical disorders
|
EP1868628B1
(en)
*
|
2005-04-08 |
2014-06-11 |
Chimerix, Inc. |
Compounds, compositions and methods for the treatment of poxvirus infections
|
EP1888052A2
(en)
*
|
2005-05-12 |
2008-02-20 |
Wisconsin Alumni Research Foundation |
Blockade of pin1 prevents cytokine production by activated immune cells
|
CA2609205A1
(en)
*
|
2005-06-03 |
2006-12-14 |
Ambrx, Inc. |
Improved human interferon molecules and their uses
|
GB0511986D0
(en)
*
|
2005-06-13 |
2005-07-20 |
Imp College Innovations Ltd |
Novel compounds and their effects on feeding behaviour
|
EP1909831A4
(en)
|
2005-06-14 |
2013-02-20 |
Amgen Inc |
PREPARATIONS OF SPONTANEOUS TAMPING PROTEINS
|
ES2569917T3
(es)
|
2005-06-21 |
2016-05-13 |
Xoma (Us) Llc |
Anticuerpos y fragmentos de los mismos que se unen a IL-1beta
|
NO345593B1
(no)
|
2005-07-18 |
2021-05-03 |
Amgen Inc |
Humane anti-B7RP1 nøytraliserende antistoffer
|
CA2616537A1
(en)
|
2005-07-27 |
2007-02-01 |
University Of Florida Research Foundation, Inc. |
Small compounds that correct protein misfolding and uses thereof
|
AU2005335491B2
(en)
*
|
2005-08-18 |
2010-11-25 |
Ambrx, Inc. |
Compositions of tRNA and uses thereof
|
KR20140077946A
(ko)
|
2005-10-13 |
2014-06-24 |
휴먼 게놈 사이언시즈, 인코포레이티드 |
자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물
|
ATE500215T1
(de)
*
|
2005-11-08 |
2011-03-15 |
Ambrx Inc |
Beschleuniger für die modifikation nichtnatürlicher aminosäuren und nichtnatürlicher aminosäurepolypeptide
|
EP2548583A3
(en)
|
2005-11-10 |
2013-02-27 |
Curagen Corporation |
Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen
|
PE20070684A1
(es)
|
2005-11-14 |
2007-08-06 |
Amgen Inc |
MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
|
ES2547554T3
(es)
|
2005-11-16 |
2015-10-07 |
Ambrx, Inc. |
Métodos y composiciones que comprenden aminoácidos no naturales
|
US20070213264A1
(en)
|
2005-12-02 |
2007-09-13 |
Mingdong Zhou |
Neuregulin variants and methods of screening and using thereof
|
US8158588B2
(en)
|
2005-12-05 |
2012-04-17 |
Simon Delagrave |
Loop-variant PDZ domains as biotherapeutics, diagnostics and research reagents
|
ATE552853T1
(de)
|
2005-12-13 |
2012-04-15 |
Medimmune Ltd |
Proteine die spezifisch insulin-ähnliche wachstumsfaktoren binden, und deren anwendungen
|
KR101423898B1
(ko)
*
|
2005-12-14 |
2014-07-28 |
암브룩스, 인코포레이티드 |
비-천연 아미노산 및 폴리펩티드를 함유하는 조성물, 비-천연 아미노산 및 폴리펩티드를 포함하는 방법, 및 비-천연 아미노산 및 폴리펩티드의 용도
|
CA2633468C
(en)
|
2005-12-14 |
2014-02-18 |
Licentia Ltd |
Novel neurotrophic factor protein and uses thereof
|
EP3168234A1
(en)
|
2005-12-15 |
2017-05-17 |
Medimmune Limited |
Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or fltl antagonist for treating cancer
|
NZ568809A
(en)
|
2005-12-22 |
2011-08-26 |
Genentech Inc |
Recovering and purification of VEGF proteins from prokaryotic cells using polyanionic agents
|
US20070190127A1
(en)
|
2005-12-30 |
2007-08-16 |
Mingdong Zhou |
Extended release of neuregulin for improved cardiac function
|
TW200813091A
(en)
|
2006-04-10 |
2008-03-16 |
Amgen Fremont Inc |
Targeted binding agents directed to uPAR and uses thereof
|
AU2007248483A1
(en)
|
2006-05-03 |
2007-11-15 |
Geisinger Clinic |
Methods for diagnosing and predicting non-alcoholic steatohepatitis (NASH)
|
US8114399B2
(en)
|
2006-05-17 |
2012-02-14 |
Ludwig Institute For Cancer Research |
Targeting VEGF-B regulation of fatty acid transporters to modulate human diseases
|
US8124743B2
(en)
|
2006-06-01 |
2012-02-28 |
President And Fellows Of Harvard College |
Purification of a bivalently active antibody using a non-chromatographic method
|
GB0611405D0
(en)
|
2006-06-09 |
2006-07-19 |
Univ Belfast |
FKBP-L: A novel inhibitor of angiogenesis
|
CA2658786A1
(en)
|
2006-07-28 |
2008-01-31 |
Children's Memorial Hospital |
Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
|
CL2007002225A1
(es)
|
2006-08-03 |
2008-04-18 |
Astrazeneca Ab |
Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
|
JP5256199B2
(ja)
|
2006-08-07 |
2013-08-07 |
テヴァ バイオファーマシューティカルズ ユーエスエー,インコーポレーティッド |
アルブミン−インスリン融合タンパク質
|
CN101541955B
(zh)
*
|
2006-09-08 |
2016-09-28 |
Ambrx公司 |
用于脊椎动物细胞的杂合抑制tRNA
|
EP2069396B1
(en)
|
2006-09-08 |
2015-10-21 |
Ambrx, Inc. |
Modified human plasma polypeptide or fc scaffolds and their uses
|
PT2064333E
(pt)
*
|
2006-09-08 |
2014-06-09 |
Ambrx Inc |
Supressor híbrido arnt para células de vertebrados
|
US7833527B2
(en)
|
2006-10-02 |
2010-11-16 |
Amgen Inc. |
Methods of treating psoriasis using IL-17 Receptor A antibodies
|
KR101503937B1
(ko)
|
2006-12-08 |
2015-03-18 |
렉시컨 파마슈티컬스 인코퍼레이티드 |
Angptl3 에 대한 단일클론 항체
|
TWI428346B
(zh)
|
2006-12-13 |
2014-03-01 |
Imp Innovations Ltd |
新穎化合物及其等對進食行為影響
|
US7695718B2
(en)
|
2006-12-20 |
2010-04-13 |
Xoma Technology Ltd. |
Methods for the treatment of IL-1β related diseases
|
US9249423B2
(en)
*
|
2007-02-02 |
2016-02-02 |
Yale University |
Method of de-differentiating and re-differentiating somatic cells using RNA
|
WO2008097926A2
(en)
*
|
2007-02-02 |
2008-08-14 |
Yale University |
Transient transfection with rna
|
US10155038B2
(en)
|
2007-02-02 |
2018-12-18 |
Yale University |
Cells prepared by transient transfection and methods of use thereof
|
TWI573802B
(zh)
|
2007-03-06 |
2017-03-11 |
安美基公司 |
變異之活動素受體多肽及其用途
|
US8501678B2
(en)
|
2007-03-06 |
2013-08-06 |
Atara Biotherapeutics, Inc. |
Variant activin receptor polypeptides and uses thereof
|
PL2068909T3
(pl)
|
2007-03-30 |
2012-09-28 |
Ambrx Inc |
Modyfikowane polipeptydy fgf-21 i ich zastosowanie
|
EP2076533B1
(en)
*
|
2007-05-02 |
2014-10-08 |
Ambrx, Inc. |
Modified interferon beta polypeptides and their uses
|
EP2153736B1
(en)
|
2007-05-11 |
2017-04-19 |
Bizen Chemical Co., Ltd. |
Novel leukotriene receptor antagonist from marine sources
|
EP2164870B1
(en)
|
2007-06-27 |
2015-12-09 |
National University of Singapore |
Polypeptides and polynucleotides for artemin and related ligands, and methods of use thereof
|
CA2696761C
(en)
|
2007-08-21 |
2017-02-14 |
Amgen Inc. |
Human c-fms antigen binding proteins
|
JOP20080381B1
(ar)
|
2007-08-23 |
2023-03-28 |
Amgen Inc |
بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
|
EP4248976A3
(en)
|
2007-08-23 |
2024-04-10 |
Amgen Inc. |
Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
|
US7982016B2
(en)
|
2007-09-10 |
2011-07-19 |
Amgen Inc. |
Antigen binding proteins capable of binding thymic stromal lymphopoietin
|
US20090156488A1
(en)
|
2007-09-12 |
2009-06-18 |
Zensun (Shanghai) Science & Technology Limited |
Use of neuregulin for organ preservation
|
TW200918553A
(en)
|
2007-09-18 |
2009-05-01 |
Amgen Inc |
Human GM-CSF antigen binding proteins
|
EP2040075A1
(en)
|
2007-09-24 |
2009-03-25 |
Julius-Maximilians-Universität Würzburg |
Compounds and markers for surface-enhanced raman scattering
|
SG187477A1
(en)
|
2007-09-26 |
2013-02-28 |
U3 Pharma Gmbh |
Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
|
ES2632504T3
(es)
*
|
2007-11-20 |
2017-09-13 |
Ambrx, Inc. |
Polipéptidos de insulina modificados y sus usos
|
CA2710252C
(en)
|
2007-12-20 |
2017-03-28 |
Xoma Technology Ltd. |
Methods for the treatment of gout
|
EP2254582B1
(en)
*
|
2008-01-25 |
2016-01-20 |
Chimerix, Inc. |
Methods of treating viral infections
|
JO2913B1
(en)
|
2008-02-20 |
2015-09-15 |
امجين إنك, |
Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
|
FI20080326A0
(fi)
|
2008-04-30 |
2008-04-30 |
Licentia Oy |
Neurotroofinen tekijä MANF ja sen käytöt
|
JOP20190083A1
(ar)
|
2008-06-04 |
2017-06-16 |
Amgen Inc |
بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
|
KR101787112B1
(ko)
|
2008-06-09 |
2017-11-15 |
루드비히-막시밀리안스-우니버지테트 뮌헨 |
신경변성 질환 및/또는 단백질 응집과 연관된 질환과 관련된 단백질의 응집을 억제하기 위한 신규 약물
|
AU2009262199B2
(en)
|
2008-06-27 |
2012-08-09 |
Amgen Inc. |
Ang-2 inhibition to treat multiple sclerosis
|
JP5680534B2
(ja)
|
2008-07-23 |
2015-03-04 |
イーライ リリー アンド カンパニー |
修飾されているウシg−csfポリペプチドおよびそれらの使用
|
JP5924937B2
(ja)
|
2008-07-25 |
2016-05-25 |
エックス−ボディ インコーポレイテッド |
タンパク質スクリーニング法
|
KR20110051245A
(ko)
|
2008-09-10 |
2011-05-17 |
제넨테크, 인크. |
안구 혈관신생의 억제 방법
|
EP2344536A1
(en)
|
2008-09-19 |
2011-07-20 |
MedImmune, LLC |
Antibodies directed to dll4 and uses thereof
|
PE20110832A1
(es)
|
2008-09-26 |
2011-11-24 |
Ambrx Inc |
Polipeptidos de eritropoyetina felina modificados
|
MX348657B
(es)
|
2008-09-26 |
2017-06-21 |
Ambrx Inc |
Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales.
|
EP2331070A1
(en)
*
|
2008-09-26 |
2011-06-15 |
Phares Pharmaceutical Research N.V. |
Method of solubilising biologically active compounds
|
UA105016C2
(uk)
|
2008-10-10 |
2014-04-10 |
Амген Інк. |
Fgf21 мутанти і їх застосування
|
CN104371024A
(zh)
|
2008-11-26 |
2015-02-25 |
安姆根有限公司 |
激活素iib受体多肽的变异体及其用途
|
US20120087870A1
(en)
|
2008-12-19 |
2012-04-12 |
Hentges Francois |
Novel caviidae allergens and uses thereof
|
EP2367564A1
(en)
|
2008-12-22 |
2011-09-28 |
Universität Regensburg |
Norrin in the treatment of diseases associated with an increased tgf-beta activity
|
JO3382B1
(ar)
|
2008-12-23 |
2019-03-13 |
Amgen Inc |
أجسام مضادة ترتبط مع مستقبل cgrp بشري
|
US20120114667A1
(en)
|
2008-12-23 |
2012-05-10 |
Medimmune Limited |
TARGETED BINDING AGENTS DIRECTED TO a5BETA1 AND USES THEREOF
|
US20110294733A1
(en)
|
2009-01-20 |
2011-12-01 |
Hanall Biopharma Co., Ltd. |
Modified human thrombopoietin polypeptide fragment and manufacturing method thereof
|
US20110014190A1
(en)
|
2009-02-12 |
2011-01-20 |
Human Genome Sciences, Inc. |
Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
|
WO2010092109A2
(en)
|
2009-02-13 |
2010-08-19 |
Novartis Ag |
Nucleic acid molecule of a biosynthetic cluster encoding non ribosomal peptide synthases and uses thereof
|
EP2427207B1
(en)
|
2009-05-05 |
2017-08-16 |
Amgen, Inc |
Fgf21 mutants and uses thereof
|
KR101860572B1
(ko)
|
2009-05-05 |
2018-05-24 |
암젠 인크 |
Fgf21 돌연변이체 및 이의 용도
|
EP2260857A1
(en)
|
2009-06-11 |
2010-12-15 |
Alfact Innovation |
Novel applications of HIP/PAP or derivatives thereof
|
IN2012DN00352A
(fi)
|
2009-06-16 |
2015-08-21 |
Bikam Pharmaceuticals Inc |
|
CA2764835A1
(en)
|
2009-06-17 |
2010-12-23 |
Amgen Inc. |
Chimeric fgf19 polypeptides and uses thereof
|
WO2011011519A1
(en)
|
2009-07-21 |
2011-01-27 |
Chimerix, Inc. |
Compounds, compositions and methods for treating ocular conditions
|
EP2305285A1
(en)
|
2009-09-29 |
2011-04-06 |
Julius-Maximilians-Universität Würzburg |
Means and methods for treating ischemic conditions
|
EP2305810A1
(en)
|
2009-10-02 |
2011-04-06 |
Technische Universität München |
miRNAs in the treatment of fibrosis
|
TW201117824A
(en)
|
2009-10-12 |
2011-06-01 |
Amgen Inc |
Use of IL-17 receptor a antigen binding proteins
|
EP2488186B1
(en)
|
2009-10-16 |
2017-05-24 |
National University of Singapore |
Anti-neoplastic uses of artemin antagonists
|
US8729058B2
(en)
|
2009-10-27 |
2014-05-20 |
Michael Zasloff |
Methods and compositions for treating and preventing viral infections
|
IL297588A
(en)
|
2009-11-02 |
2022-12-01 |
Univ Washington |
Therapeutic nuclease preparations and methods
|
CA2780761A1
(en)
|
2009-11-13 |
2011-05-19 |
Puget Sound Blood Center |
Factor viii t cell epitope variants having reduced immunogenicity
|
BR122021025338B1
(pt)
|
2009-11-24 |
2023-03-14 |
Medimmune Limited |
Anticorpo isolado ou fragmento de ligação do mesmo contra b7-h1, composição farmacêutica e seus usos
|
US8623416B2
(en)
|
2009-11-25 |
2014-01-07 |
Michael Zasloff |
Formulations comprising aminosterols
|
US8491927B2
(en)
|
2009-12-02 |
2013-07-23 |
Nimble Epitech, Llc |
Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
|
UA109888C2
(uk)
|
2009-12-07 |
2015-10-26 |
|
ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
|
CN102666578A
(zh)
|
2009-12-21 |
2012-09-12 |
Ambrx公司 |
经过修饰的猪促生长素多肽和其用途
|
EA201290541A1
(ru)
|
2009-12-21 |
2013-05-30 |
Амбркс, Инк. |
Модифицированные бычьи соматотропиновые полипептиды и их применение
|
WO2011089161A1
(en)
|
2010-01-19 |
2011-07-28 |
Medizinische Universität Wien |
Pharmaceutical compositions comprising lignans and their derivatives for the medical management of angiogenesis and hypovascularity
|
JP6046493B2
(ja)
|
2010-01-27 |
2016-12-14 |
チルドレンズ メディカル センター コーポレーション |
プロミニン−1の血管新生促進フラグメントおよびその使用
|
US8778416B2
(en)
|
2010-02-10 |
2014-07-15 |
Nayacure Therapeutics Ltd. |
Pharmaceutical compositions and methods for the treatment and prevention of cancer
|
US9006218B2
(en)
|
2010-02-12 |
2015-04-14 |
Chimerix Inc. |
Nucleoside phosphonate salts
|
JP2013523184A
(ja)
|
2010-04-15 |
2013-06-17 |
アムジエン・インコーポレーテツド |
ヒトFGF受容体およびβ−KLOTHO結合性タンパク質
|
US20130116304A1
(en)
|
2010-04-19 |
2013-05-09 |
Ernst R. Werner |
Tmem195 encodes for tetrahydrobiopterin-dependent alkylglycerol monooxygenase activity
|
EP2563367A4
(en)
|
2010-04-26 |
2013-12-04 |
Chimerix Inc |
METHODS OF TREATING RETROVIRAL INFECTIONS AND ASSOCIATED DOSAGE REGIMES
|
WO2011138457A1
(en)
|
2010-05-07 |
2011-11-10 |
Technische Universität Graz |
Ucp1 (thermogenin) - inducing agents for use in the treatment of a disorder of the energy homeostasis
|
JP6033218B2
(ja)
|
2010-05-21 |
2016-11-30 |
ペプティメド, インコーポレイテッド |
がんを治療するための試薬および方法
|
EP2580240B1
(en)
|
2010-06-14 |
2018-11-28 |
Lykera Biomed S.A. |
S100a4 antibodies and therapeutic uses thereof
|
CA2802635A1
(en)
|
2010-06-18 |
2011-12-22 |
Xiberscience Gmbh |
Peptides as active agents to stabilize biologic barriers
|
US9567386B2
(en)
|
2010-08-17 |
2017-02-14 |
Ambrx, Inc. |
Therapeutic uses of modified relaxin polypeptides
|
CA2808596C
(en)
|
2010-08-17 |
2020-12-15 |
Ambrx, Inc. |
Modified relaxin polypeptides and their uses
|
AR083006A1
(es)
|
2010-09-23 |
2013-01-23 |
Lilly Co Eli |
Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
|
CA2815181C
(en)
|
2010-10-27 |
2020-09-15 |
William Gleason Richards |
Dkk1 antibodies and methods of use
|
JP6189215B2
(ja)
|
2010-11-01 |
2017-08-30 |
ペプチメッド, インコーポレイテッド |
細胞特異的ターゲティングのためのペプチドに基づいたシステムの組成物
|
US9023791B2
(en)
|
2010-11-19 |
2015-05-05 |
Novartis Ag |
Fibroblast growth factor 21 mutations
|
ES2718849T3
(es)
|
2010-11-24 |
2019-07-04 |
Lexicon Pharmaceuticals Inc |
Anticuerpos contra notum pectinacetilesterasa
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
US9228011B2
(en)
|
2011-01-17 |
2016-01-05 |
Lykera Biomed Sa |
Antibodies against the S100P protein for the treatment and diagnosis of cancer
|
SG10201600531TA
(en)
|
2011-01-24 |
2016-02-26 |
Univ Singapore |
Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
|
US9708366B2
(en)
|
2011-01-27 |
2017-07-18 |
Neuren Pharmaceuticals Ltd. |
Treatment of fragile X syndrome using glycyl-L-2-methylprolyl-L-glutamate
|
MX2013010011A
(es)
|
2011-03-01 |
2014-10-24 |
Amgen Inc |
Agentes de unión biespecífica.
|
MX2013010185A
(es)
|
2011-03-10 |
2014-02-17 |
Genentech Inc |
Tratamiento de alteraciones con funcion de barrera vascular alterada.
|
CN103619881B
(zh)
|
2011-04-07 |
2017-07-28 |
安姆根有限公司 |
新的egfr结合蛋白
|
EP2694092B1
(en)
|
2011-04-08 |
2017-01-04 |
Amgen Inc. |
Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
|
EP2704737B1
(en)
|
2011-04-29 |
2018-01-10 |
University of Washington |
Therapeutic nuclease compositions and methods
|
JOP20200043A1
(ar)
|
2011-05-10 |
2017-06-16 |
Amgen Inc |
طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
|
US20140189893A1
(en)
|
2011-05-10 |
2014-07-03 |
Amgen Inc. |
Method of identifying compounds that specifically modulate the interaction of fgfr1 and beta klotho
|
US9574002B2
(en)
|
2011-06-06 |
2017-02-21 |
Amgen Inc. |
Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
|
WO2012174064A1
(en)
|
2011-06-14 |
2012-12-20 |
Bikam Pharmaceuticals, Inc. |
Opsin-binding ligands, compositions and methods of use
|
MX2013014847A
(es)
|
2011-06-17 |
2015-01-12 |
Amgen Inc |
Metodo para tratar o aminorar trastornos metabolicos udando clec-2.
|
WO2013016220A1
(en)
|
2011-07-22 |
2013-01-31 |
Amgen Inc. |
Il-17 receptor a is required for il-17c biology
|
WO2013017656A1
(en)
|
2011-08-02 |
2013-02-07 |
Medizinische Universität Wien |
Antagonists of ribonucleases for treating obesity
|
EP2744828A4
(en)
|
2011-08-16 |
2014-12-31 |
Univ Emory |
JAML-SPECIFIC BINDING AGENTS, ANTIBODIES AND USES THEREOF
|
CA2843369A1
(en)
|
2011-08-16 |
2013-02-21 |
Evotec (Munchen) Gmbh |
Markers for susceptibility to an inhibitor of an src-family kinase
|
MX2014002260A
(es)
|
2011-08-31 |
2014-08-18 |
Amgen Inc |
Factor de crecimiento de fibroblasto 21 para usar en el tratamiento de diabetes tipo 1.
|
ES2806146T3
(es)
|
2011-09-22 |
2021-02-16 |
Amgen Inc |
Proteínas de unión al antígeno CD27L
|
US9458214B2
(en)
|
2011-09-26 |
2016-10-04 |
Novartis Ag |
Dual function fibroblast growth factor 21 proteins
|
JO3476B1
(ar)
|
2011-09-26 |
2020-07-05 |
Novartis Ag |
بروتينات مندمجة لعلاج الاضطرابات الايضية
|
WO2013053076A1
(en)
|
2011-10-10 |
2013-04-18 |
Zensun (Shanghai)Science & Technology Limited |
Compositions and methods for treating heart failure
|
US8906860B2
(en)
|
2011-10-14 |
2014-12-09 |
The Board Of Trustees Of The University Of Illinois |
Methods and compositions inhibiting tumor cell proliferation
|
US20130172265A1
(en)
|
2011-10-14 |
2013-07-04 |
The Board Of Trustees Of The University Of Illinois |
Methods and Compositions for Inhibiting Tumor Cell Proliferation
|
PE20141937A1
(es)
|
2011-11-16 |
2014-12-18 |
Amgen Inc |
Metodos para tratar trastornos relacionados con mutante viii de eliminacion de factor de crecimiento epidermico
|
GR1007832B
(el)
|
2011-11-21 |
2013-02-14 |
Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, |
Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη"
|
EP2944628B1
(en)
|
2011-11-30 |
2017-01-04 |
Bikam Pharmaceuticals, Inc. |
Opsin-binding ligands, compositions and methods of use
|
EP2601941A1
(en)
|
2011-12-06 |
2013-06-12 |
Ludwig-Maximilians-Universität München |
Beta-O/S/N fatty acid based compounds as antibacterial and antiprotozoal agents
|
CN104220460A
(zh)
|
2011-12-08 |
2014-12-17 |
安姆根有限公司 |
激动人lcat抗原结合蛋白和它们在疗法中的用途
|
WO2013083810A1
(en)
|
2011-12-09 |
2013-06-13 |
F. Hoffmann-La Roche Ag |
Identification of non-responders to her2 inhibitors
|
MX358358B
(es)
|
2011-12-19 |
2018-08-15 |
Amgen Inc |
Polipeptidos de receptores de activina variantes y sus usos.
|
WO2013096516A1
(en)
|
2011-12-19 |
2013-06-27 |
Xoma Technology Ltd. |
Methods for treating acne
|
CA2863224A1
(en)
|
2012-01-09 |
2013-07-18 |
The Scripps Research Institute |
Ultralong complementarity determining regions and uses thereof
|
JP2015509091A
(ja)
|
2012-01-09 |
2015-03-26 |
ザ スクリプス リサーチ インスティテュート |
ヒト化抗体
|
BR112014018575A2
(pt)
|
2012-01-26 |
2017-07-04 |
Amgen Inc |
polipetídeos de fator de diferenciação de crescimento 15 (gdf-15)
|
EP2626066A1
(en)
|
2012-02-10 |
2013-08-14 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Combination therapy comprising selective VEGFR-2 inhibitors and MEK inhibitors
|
EA039663B1
(ru)
|
2012-05-03 |
2022-02-24 |
Амген Инк. |
Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
|
WO2013172954A1
(en)
|
2012-05-17 |
2013-11-21 |
Ra Pharmaceuticals, Inc |
Peptide and peptidomimetic inhibitors
|
AR091069A1
(es)
|
2012-05-18 |
2014-12-30 |
Amgen Inc |
Proteinas de union a antigeno dirigidas contra el receptor st2
|
EP2666775A1
(en)
|
2012-05-21 |
2013-11-27 |
Domain Therapeutics |
Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
|
WO2013177187A2
(en)
|
2012-05-22 |
2013-11-28 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
|
AU2013285537B2
(en)
|
2012-07-02 |
2017-10-12 |
Medizinische Universitat Wien |
Complement split product C4d for the treatment of inflammatory conditions
|
EP2687225A1
(en)
|
2012-07-19 |
2014-01-22 |
Alfact Innovation |
HIP/PAP protein and derivatives thereof for use in treating cancer
|
EP2695950A1
(en)
|
2012-08-10 |
2014-02-12 |
Blackfield AG |
Markers for responsiveness to an inhibitor of the fibroblast growth factor receptor
|
WO2014031649A1
(en)
|
2012-08-21 |
2014-02-27 |
Genesys Research Institute |
Compositions and methods for treating or preventing anthracycline induced cardiotoxicity
|
US9309318B2
(en)
|
2012-10-17 |
2016-04-12 |
Amgen, Inc. |
Compositions relating to anti-IL-21 receptor antibodies
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
RU2692773C2
(ru)
|
2012-11-30 |
2019-06-27 |
Ф.Хоффманн-Ля Рош Аг |
Идентификация пациентов, нуждающихся в совместной терапии с использованием ингибитора pd-l1
|
TW201425336A
(zh)
|
2012-12-07 |
2014-07-01 |
Amgen Inc |
Bcma抗原結合蛋白質
|
JO3519B1
(ar)
|
2013-01-25 |
2020-07-05 |
Amgen Inc |
تركيبات أجسام مضادة لأجل cdh19 و cd3
|
ES2728936T3
(es)
|
2013-01-25 |
2019-10-29 |
Amgen Inc |
Anticuerpos dirigidos contra CDH19 para melanoma
|
MX2015009901A
(es)
|
2013-02-01 |
2016-04-06 |
Santa Maria Biotherapeutics Inc |
Administración de un compuesto de antiactivina a a un sujeto.
|
JOP20140087B1
(ar)
|
2013-03-13 |
2021-08-17 |
Amgen Inc |
بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
|
US9458246B2
(en)
|
2013-03-13 |
2016-10-04 |
Amgen Inc. |
Proteins specific for BAFF and B7RP1
|
US9580486B2
(en)
|
2013-03-14 |
2017-02-28 |
Amgen Inc. |
Interleukin-2 muteins for the expansion of T-regulatory cells
|
AU2014244444A1
(en)
|
2013-03-14 |
2015-09-24 |
Amgen Inc. |
CHRDL-1 antigen binding proteins and methods of treatment
|
AU2014236728B2
(en)
|
2013-03-15 |
2018-09-13 |
Amgen Inc. |
Method of treating metabolic disorders using PLA2G12A polypeptides and PLA2G12A mutant polypeptides
|
AU2014228924B2
(en)
|
2013-03-15 |
2019-04-18 |
Amgen Inc. |
Human PAC1 antibodies
|
HUE045859T2
(hu)
|
2013-03-15 |
2020-01-28 |
Amgen Res Munich Gmbh |
N-terminális ABP-t tartalmazó, egyláncú kötõmolekulák
|
EP2970446A1
(en)
|
2013-03-15 |
2016-01-20 |
Amgen Research (Munich) GmbH |
Antibody constructs for influenza m2 and cd3
|
WO2014144553A1
(en)
|
2013-03-15 |
2014-09-18 |
Amgen Inc. |
Secreted frizzle-related protein 5 (sfrp5) binding proteins and methods of treatment
|
AU2014236867A1
(en)
|
2013-03-15 |
2015-09-24 |
Amgen Inc. |
Methods and compositions relating to anti-CCR7 antigen binding proteins
|
WO2014144817A2
(en)
|
2013-03-15 |
2014-09-18 |
Amgen Inc. |
Inhibitory polypeptides specific to wnt inhibitors
|
EP2984108B1
(en)
|
2013-04-09 |
2017-05-31 |
Lykera Biomed, S.A. |
Anti-s100a7 antibodies for the treatment and diagnosis of cancer
|
EP2801370A1
(en)
|
2013-05-07 |
2014-11-12 |
Fundació Privada Institut d'Investigació Oncològica de Vall Hebron |
Methods and compositions for the treatment of cancer
|
EP2999797B1
(en)
|
2013-05-21 |
2018-07-04 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Isoforms of gata6 and nkx2-1 as markers for diagnosis and therapy of cancer and as targets for anti-cancer therapy
|
EP3895724A1
(en)
|
2013-05-22 |
2021-10-20 |
Zensun (Shanghai) Science and Technology, Co., Ltd. |
Extended release of neuregulin for treating heart failure
|
WO2014191630A2
(en)
|
2013-05-28 |
2014-12-04 |
Helsingin Yliopisto |
Non-human animal model encoding a non-functional manf gene
|
CN110511279B
(zh)
|
2013-05-30 |
2024-03-29 |
基尼克萨制药有限公司 |
制瘤素m受体抗原结合蛋白
|
EP2810648A1
(en)
|
2013-06-04 |
2014-12-10 |
Daniel Rauh |
Targeting domain-domain interaction for the identification of kinase modulators
|
EP2835135A3
(en)
|
2013-06-19 |
2015-06-24 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin |
Means and methods for treating pseudomonas infection
|
CA2916259C
(en)
|
2013-06-28 |
2024-02-20 |
Amgen Inc. |
Methods for treating homozygous familial hypercholesterolemia
|
WO2014207213A1
(en)
|
2013-06-28 |
2014-12-31 |
Medizinische Universität Innsbruck |
Novel inhibitors of protein kinase c epsilon signaling
|
WO2015017146A2
(en)
|
2013-07-18 |
2015-02-05 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
EP3022221B1
(en)
|
2013-07-18 |
2021-09-15 |
Taurus Biosciences, LLC |
Humanized antibodies with ultralong complementarity determining regions
|
PT3027642T
(pt)
|
2013-07-31 |
2020-10-30 |
Amgen Inc |
Construtos do fator 15 de diferenciação de crescimento (gdf-15)
|
WO2015022326A1
(en)
|
2013-08-12 |
2015-02-19 |
Xiber Science Gmbh |
Peptides as active agents for treating primary graft dysfunction
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
JP6668241B2
(ja)
|
2013-09-05 |
2020-03-18 |
アムジエン・インコーポレーテツド |
予測可能で、一貫性のある、且つ再現可能な糖型特性を示すFc含有分子
|
AR097648A1
(es)
|
2013-09-13 |
2016-04-06 |
Amgen Inc |
Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide
|
US10286078B2
(en)
|
2013-09-13 |
2019-05-14 |
The California Institute For Biomedical Research |
Modified therapeutic agents and compositions thereof
|
SG11201601193TA
(en)
|
2013-09-16 |
2016-04-28 |
Cemm Forschungszentrum Für Molekulare Medizin Gmbh |
Mutant calreticulin for the diagnosis of myeloid malignancies
|
DK3049521T3
(en)
|
2013-09-25 |
2019-04-23 |
Univ Cornell |
Compounds for inducing antitumor immunity and methods thereof
|
ES2741308T3
(es)
|
2013-10-15 |
2020-02-10 |
Scripps Research Inst |
Interruptores de células T con receptores de antígenos quiméricos y usos de los mismos
|
EP3057994B1
(en)
|
2013-10-15 |
2020-09-23 |
The Scripps Research Institute |
Peptidic chimeric antigen receptor t cell switches and uses thereof
|
WO2015057908A1
(en)
|
2013-10-18 |
2015-04-23 |
Novartis Ag |
Methods of treating diabetes and related disorders
|
SI3063275T1
(sl)
|
2013-10-31 |
2020-02-28 |
Resolve Therapeutics, Llc |
Terapevtske fuzije nukleaza-albumin in postopki
|
GB201319374D0
(en)
|
2013-11-01 |
2013-12-18 |
Univ Nottingham |
Glycans as functional cancer targets abd antibodies thereto
|
CN106456589B
(zh)
|
2013-12-18 |
2020-07-07 |
斯克利普斯研究所 |
修饰的治疗剂、订合的肽脂质缀合物及其组合物
|
CN103965357B
(zh)
|
2013-12-31 |
2016-08-17 |
嘉和生物药业有限公司 |
一种抗人rankl抗体
|
WO2015110930A1
(en)
|
2014-01-24 |
2015-07-30 |
Pfizer Inc. |
Modified interleukin 21 receptor proteins
|
WO2015121457A1
(en)
|
2014-02-13 |
2015-08-20 |
Westphal Sören |
Fgf-8 for use in treating diseases or disorders of energy homeostasis
|
RU2019119857A
(ru)
|
2014-02-20 |
2019-07-12 |
Аллерган, Инк. |
Антитела к компоненту комплемента c5
|
WO2015130826A1
(en)
|
2014-02-27 |
2015-09-03 |
Allergan, Inc. |
COMPLEMENT FACTOR Bb ANTIBODIES
|
CA2888068A1
(en)
|
2014-04-15 |
2015-10-15 |
The Hospital For Sick Children |
Cationic antimicrobial peptides
|
EP3143143A1
(en)
|
2014-05-15 |
2017-03-22 |
CeMM - Forschungszentrum für Molekulare Medizin GmbH |
Antagonists of slc38a9 and their use in therapy
|
WO2015179415A1
(en)
|
2014-05-19 |
2015-11-26 |
Novartis Ag |
Methods of treating anorexia
|
EP2947460A1
(en)
|
2014-05-22 |
2015-11-25 |
Medizinische Universität Wien |
Personalized therapy of inflammation-associated cancer using methods of assessing the susceptibility of a subject to the treatment with EGFR inhibitors/antagonists
|
EA201692568A1
(ru)
|
2014-06-13 |
2017-05-31 |
Санта Мария Биотерапевтикс, Инк. |
Составы с полипептидами-рецепторами и связанные с ними способы
|
AR101669A1
(es)
|
2014-07-31 |
2017-01-04 |
Amgen Res (Munich) Gmbh |
Constructos de anticuerpos para cdh19 y cd3
|
JP6749312B2
(ja)
|
2014-07-31 |
2020-09-02 |
アムゲン リサーチ (ミュンヘン) ゲーエムベーハーAMGEN Research(Munich)GmbH |
最適化された種間特異的二重特異性単鎖抗体コンストラクト
|
WO2016025401A1
(en)
*
|
2014-08-09 |
2016-02-18 |
Avanti Polar Lipids, Inc. |
Oral composition for delivery of drugs and other substances
|
CA3133162C
(en)
|
2014-08-12 |
2024-02-13 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein
|
US20170224777A1
(en)
|
2014-08-12 |
2017-08-10 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
|
EP3183346A4
(en)
|
2014-08-22 |
2018-10-24 |
Auckland Uniservices Limited |
Channel modulators
|
EP3186378A1
(en)
|
2014-08-27 |
2017-07-05 |
Peptimed, Inc. |
Anti-tumor compositions and methods
|
WO2016040767A2
(en)
|
2014-09-12 |
2016-03-17 |
Amgen Inc. |
Chrdl-1 epitopes and antibodies
|
EP3000814A1
(en)
|
2014-09-26 |
2016-03-30 |
Domain Therapeutics |
Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
|
JP6702962B2
(ja)
|
2014-10-24 |
2020-06-03 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
改変fgf−21ポリペプチドおよびその使用
|
WO2016069889A1
(en)
|
2014-10-31 |
2016-05-06 |
Resolve Therapeutics, Llc |
Therapeutic nuclease-transferrin fusions and methods
|
WO2016079321A1
(en)
|
2014-11-20 |
2016-05-26 |
Cemm Forschungszentrum Für Molekulare Medizin Gmbh |
Antagonists of setdb2 for use in the therapy of infectious diseases
|
EP3085709B1
(en)
|
2014-12-28 |
2019-08-21 |
Genor Biopharma Co., Ltd |
Humanized anti-human rankl antibody, pharmaceutical composition and use thereof
|
EP3250609A4
(en)
|
2015-01-26 |
2018-07-11 |
The University of Chicago |
Il13ra alpha 2 binding agents and use thereof in cancer treatment
|
CN107835820B
(zh)
|
2015-01-26 |
2021-10-15 |
芝加哥大学 |
识别癌症特异性IL13Rα2的CAR T细胞
|
WO2016135138A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Oxoquinoline derivatives as mth1 inhibitors for the therapy of cancer
|
CA2976593A1
(en)
|
2015-02-23 |
2016-09-01 |
Seagull Therapeutics Sas |
Non-natural semaphorins 3 and their medical use
|
WO2016135140A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
4-aminoquinazoline derivatives as mth1 inhibitors for the therapy of cancer
|
WO2016135137A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Substituted 4-(phenylamino)quinoline derivatives as mth1 inhibitors for the therapy of cancer
|
WO2016135139A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
2,3-dihydrocyclopenta[b]quinoline derivatives as mth1 inhibitors for the therapy of cancer
|
US10800828B2
(en)
|
2015-03-26 |
2020-10-13 |
The Scripps Research Institute |
Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
|
EA201792250A1
(ru)
|
2015-04-10 |
2018-05-31 |
Эмджен Инк. |
Мутеины интерлейкина-2 для роста регуляторных т-клеток
|
US11091546B2
(en)
|
2015-04-15 |
2021-08-17 |
The Scripps Research Institute |
Optimized PNE-based chimeric receptor T cell switches and uses thereof
|
PT3283524T
(pt)
|
2015-04-17 |
2023-06-05 |
Amgen Res Munich Gmbh |
Construções de anticorpos biespecíficos para cdh3 e cd3
|
US10864190B2
(en)
|
2015-04-22 |
2020-12-15 |
CeMM—FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GmbH |
Combination of an antiandrogen with a vitamin K antagonist or with a gamma-glutamyl carboxylase inhibitor for the therapy of androgen receptor positive cancer
|
US20160361380A1
(en)
|
2015-06-12 |
2016-12-15 |
Nymox Corporation |
Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
|
EP3310376A4
(en)
|
2015-06-17 |
2019-01-23 |
The California Institute for Biomedical Research |
MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
|
WO2017007955A1
(en)
|
2015-07-07 |
2017-01-12 |
The Research Foundation For The State University Of New York |
Use of amine carboxyboranes as therapeutic delivery of carbon monoxide and as general drug delivery system in the presence of reactive oxygen species
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究(慕尼黑)公司 |
Egfrviii及cd3抗體構築體
|
TW202346349A
(zh)
|
2015-07-31 |
2023-12-01 |
德商安美基研究(慕尼黑)公司 |
Dll3及cd3抗體構築體
|
TWI717375B
(zh)
|
2015-07-31 |
2021-02-01 |
德商安美基研究(慕尼黑)公司 |
Cd70及cd3抗體構築體
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究(慕尼黑)公司 |
Flt3及cd3抗體構築體
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究(慕尼黑)公司 |
Msln及cd3抗體構築體
|
JO3620B1
(ar)
|
2015-08-05 |
2020-08-27 |
Amgen Res Munich Gmbh |
مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
|
US20180280474A1
(en)
|
2015-10-01 |
2018-10-04 |
Amgen Inc. |
Treatment of bile acid disorders
|
US20180320136A1
(en)
|
2015-11-03 |
2018-11-08 |
GlycoMimitics, Inc. |
Methods and compositions for the production of monoclonal antibodies, hematopoietic stem cells, and methods of using the same
|
BR112018009550A2
(pt)
|
2015-11-13 |
2018-11-06 |
Mavalon Therapeutics Ltd |
derivados de 1,4-benzodiazepinona tricíclica substituída como moduladores alostéricos de receptores de glutamato metabotrópico de grupo ii
|
US20170157215A1
(en)
|
2015-12-04 |
2017-06-08 |
Jomoco, Corp. |
Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
|
PL3386997T3
(pl)
|
2015-12-09 |
2021-12-13 |
Medizinische Universität Wien |
Funkcjonalizowane monomaleimidem związki platyny do terapii nowotworowej
|
PE20181327A1
(es)
|
2015-12-23 |
2018-08-20 |
Amgen Inc |
Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1
|
EP3402788A1
(en)
|
2016-01-15 |
2018-11-21 |
Universität Hamburg |
Flavonoide-type compounds bearing an o-rhamnosyl residue
|
JOP20170017B1
(ar)
|
2016-01-25 |
2021-08-17 |
Amgen Res Munich Gmbh |
تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص
|
EA039859B1
(ru)
|
2016-02-03 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
KR20180101623A
(ko)
|
2016-02-03 |
2018-09-12 |
암젠 리서치 (뮌헨) 게엠베하 |
Psma 및 cd3 이중특이성 t 세포 맞물림 항체 작제물
|
MA43955B1
(fr)
|
2016-02-03 |
2022-02-28 |
Amgen Inc |
Anticorps anti-bcma et anti-cd3 bispécifiques de format bite
|
MX2018009870A
(es)
|
2016-02-15 |
2018-11-29 |
Cemm Forschungszentrum Fuer Molekulare Medizin Gmbh |
Inhibidores de taf1 para la terapia del cancer.
|
EP3216458A1
(en)
|
2016-03-07 |
2017-09-13 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Modified vascular endothelial growth factor a (vegf-a) and its medical use
|
WO2017176916A1
(en)
|
2016-04-05 |
2017-10-12 |
The Research Foundation For The State University Of New York |
Phosphoserine containing compositions for immune tolerance induction
|
US20190111069A1
(en)
|
2016-04-15 |
2019-04-18 |
Oxford University Innovation Limited |
Adenosine Receptor Modulators for the Treatment of Circadian Rhythm Disorders
|
JP7422480B2
(ja)
|
2016-05-04 |
2024-01-26 |
アムジエン・インコーポレーテツド |
制御性t細胞の増殖のためのインターロイキン-2変異タンパク質
|
US10183058B2
(en)
|
2016-06-17 |
2019-01-22 |
Nymox Corporation |
Method of preventing or reducing the progression of prostate cancer
|
US20190241878A1
(en)
|
2016-07-01 |
2019-08-08 |
Resolve Therapeutics, Llc |
Optimized binuclease fusions and methods
|
EP3269734A1
(en)
|
2016-07-15 |
2018-01-17 |
Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron |
Methods and compositions for the treatment of cancer
|
US10300145B2
(en)
|
2016-07-15 |
2019-05-28 |
Massachusetts Institute Of Technology |
Synthetic nanoparticles for delivery of immunomodulatory compounds
|
US10172910B2
(en)
|
2016-07-28 |
2019-01-08 |
Nymox Corporation |
Method of preventing or reducing the incidence of acute urinary retention
|
EP3493848B1
(en)
|
2016-08-02 |
2021-09-29 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Heterocyclic diamidines
|
JP2019527710A
(ja)
|
2016-08-08 |
2019-10-03 |
アムジエン・インコーポレーテツド |
抗スクレロスチン抗体を用いた結合組織付着の改善方法
|
US10532081B2
(en)
|
2016-09-07 |
2020-01-14 |
Nymox Corporation |
Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
|
EP3529268A1
(en)
|
2016-10-19 |
2019-08-28 |
The Scripps Research Institute |
Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
|
MX2019005443A
(es)
|
2016-11-14 |
2019-11-21 |
Cemm Forschungszentrum Fuer Molekulare Medizin Gmbh |
Combinacion de un inhibidor de brd4 y un antifolato para la terapia del cancer.
|
EP3548488A1
(en)
|
2016-11-30 |
2019-10-09 |
Oncotyrol Center for Personalized Cancer Medicine GmbH |
3-amino-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-ones as cyclin dependent kinase inhibitors
|
AU2018206279B2
(en)
|
2017-01-06 |
2020-09-03 |
Abl Bio Inc. |
Anti-alpha-syn antibody and use thereof
|
JOP20190177A1
(ar)
|
2017-01-17 |
2019-07-16 |
Amgen Inc |
طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
|
JOP20190189A1
(ar)
|
2017-02-02 |
2019-08-01 |
Amgen Res Munich Gmbh |
تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
|
CN110637027A
(zh)
|
2017-02-08 |
2019-12-31 |
百时美施贵宝公司 |
包含药代动力学增强子的修饰的松弛素多肽及其用途
|
US10335453B2
(en)
|
2017-03-01 |
2019-07-02 |
Nymox Corporation |
Compositions and methods for improving sexual function
|
US11021529B2
(en)
|
2017-03-03 |
2021-06-01 |
Massachusetts Institute Of Technology |
Antimicrobial constructs and uses thereof
|
SG11201909547TA
(en)
|
2017-05-05 |
2019-11-28 |
Amgen Inc |
Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration
|
CN110769830A
(zh)
|
2017-05-12 |
2020-02-07 |
马瓦隆治疗有限公司 |
作为ii组代谢型谷氨酸受体的别构调节剂的取代的杂环化合物
|
EP3634403A1
(en)
|
2017-05-12 |
2020-04-15 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Phenyl-heterocycle-phenyl derivatives for use in the treatment or prevention of melanoma
|
JOP20190259A1
(ar)
|
2017-05-31 |
2019-10-31 |
Amgen Inc |
بروتينات ربط مولد ضد مضادة لـ jagged1
|
WO2018236904A1
(en)
|
2017-06-19 |
2018-12-27 |
Surface Oncology, Inc. |
COMBINATION OF ANTI-CD47 ANTIBODIES AND CELL DEATH INDUCING AGENTS, AND USES THEREOF
|
CR20190532A
(es)
|
2017-06-20 |
2020-01-10 |
Amgen Inc |
Método para tratar o mejorar trastornos metabólicos con proteínas de unión para el receptor peptídico inhibidor gástrico (gipr) en combinación con agonistas de glp-1
|
SG10201913144TA
(en)
|
2017-07-11 |
2020-03-30 |
Compass Therapeutics Llc |
Agonist antibodies that bind human cd137 and uses thereof
|
CA3070089A1
(en)
|
2017-07-19 |
2019-01-24 |
Auckland Uniservices Limited |
Cytokine modulation
|
US11077199B2
(en)
|
2017-08-09 |
2021-08-03 |
Massachusetts Institute Of Technology |
Albumin binding peptide conjugates and methods thereof
|
WO2019036605A2
(en)
|
2017-08-17 |
2019-02-21 |
Massachusetts Institute Of Technology |
MULTIPLE SPECIFICITY BINDING AGENTS OF CXC CHEMOKINES AND USES THEREOF
|
MX2020002070A
(es)
|
2017-08-22 |
2020-03-24 |
Sanabio Llc |
Receptores solubles de interferon y usos de los mismos.
|
WO2019060425A1
(en)
|
2017-09-19 |
2019-03-28 |
Massachusetts Institute Of Technology |
COMPOSITIONS FOR CHIMERIC ANTIGENIC RECEPTOR T CELL THERAPY AND USES THEREOF
|
KR20200059281A
(ko)
|
2017-10-04 |
2020-05-28 |
암젠 인크 |
트랜스타이레틴 면역글로불린 융합
|
EP3704132A4
(en)
|
2017-10-30 |
2021-07-28 |
Enterin, Inc. |
NEW SOLID FORMS OF SQUALAMINE AND PROCESSES FOR PRODUCING THEM
|
WO2019089753A2
(en)
|
2017-10-31 |
2019-05-09 |
Compass Therapeutics Llc |
Cd137 antibodies and pd-1 antagonists and uses thereof
|
EP3713961A2
(en)
|
2017-11-20 |
2020-09-30 |
Compass Therapeutics LLC |
Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
WO2019110139A1
(en)
|
2017-12-05 |
2019-06-13 |
Eth Zurich |
New compounds for use as a therapeutically active substance and in particular for use in the treatment of tumors
|
BR112020011627A2
(pt)
|
2017-12-11 |
2020-11-17 |
Amgen Inc. |
processo de fabricação contínuo para produtos de anticorpos biespecíficos
|
JP2021506851A
(ja)
|
2017-12-19 |
2021-02-22 |
マサチューセッツ インスティテュート オブ テクノロジー |
抗原−アジュバントカップリング試薬および使用の方法
|
TW201940518A
(zh)
|
2017-12-29 |
2019-10-16 |
美商安進公司 |
針對muc17和cd3之雙特異性抗體構建體
|
KR20230020023A
(ko)
|
2018-03-14 |
2023-02-09 |
서피스 온콜로지, 인크. |
Cd39에 결합하는 항체 및 이의 용도
|
CA3093740A1
(en)
|
2018-03-22 |
2019-09-26 |
Surface Oncology, Inc. |
Anti-il-27 antibodies and uses thereof
|
AU2019243595A1
(en)
|
2018-03-30 |
2020-09-17 |
Amgen Inc. |
C-terminal antibody variants
|
EA202092326A1
(ru)
|
2018-04-06 |
2021-03-19 |
Цилентин Аг |
Производные буметанида для лечения гипергидроза
|
WO2019193161A1
(en)
|
2018-04-06 |
2019-10-10 |
Universität Wien |
Bumetanide derivatives for the therapy of stroke and other neurological diseases/disorders involving nkccs
|
AU2019253462A1
(en)
|
2018-04-09 |
2020-11-26 |
Amgen Inc. |
Growth differentiation factor 15 fusion proteins
|
WO2019200357A1
(en)
|
2018-04-12 |
2019-10-17 |
Surface Oncology, Inc. |
Biomarker for cd47 targeting therapeutics and uses therefor
|
EP3781689A1
(en)
|
2018-04-19 |
2021-02-24 |
Checkmate Pharmaceuticals, Inc. |
Synthetic rig-i-like receptor agonists
|
WO2019207051A1
(en)
|
2018-04-25 |
2019-10-31 |
Università Degli Studi Di Torino |
Medical use of combinations of non-natural semaphorins 3 and antimetabolites
|
CA3099308A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Compositions and methods for enhancing the killing of target cells by nk cells
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
WO2019225787A1
(ko)
|
2018-05-24 |
2019-11-28 |
에이비엘바이오 주식회사 |
항-b7-h3 항체 및 그 용도
|
US20220275043A1
(en)
|
2018-07-17 |
2022-09-01 |
Massachusetts Institute Of Technology |
Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof
|
WO2020033926A2
(en)
|
2018-08-09 |
2020-02-13 |
Compass Therapeutics Llc |
Antibodies that bind cd277 and uses thereof
|
US20210388089A1
(en)
|
2018-08-09 |
2021-12-16 |
Compass Therapeutics Llc |
Antigen binding agents that bind cd277 and uses thereof
|
WO2020033925A2
(en)
|
2018-08-09 |
2020-02-13 |
Compass Therapeutics Llc |
Antibodies that bind cd277 and uses thereof
|
AU2019327456A1
(en)
|
2018-08-28 |
2021-04-15 |
Ambrx, Inc. |
anti-CD3 antibody folate bioconjugates and their uses
|
PL3849614T3
(pl)
|
2018-09-11 |
2024-04-22 |
Ambrx, Inc. |
Koniugaty polipeptydu interleukiny-2 i ich zastosowania
|
WO2020053808A1
(en)
|
2018-09-12 |
2020-03-19 |
Georg Dewald |
Method of diagnosing vasoregulatory disorders
|
CA3113618A1
(en)
|
2018-09-28 |
2020-04-02 |
Massachusetts Institute Of Technology |
Collagen-localized immunomodulatory molecules and methods thereof
|
SG11202103275YA
(en)
|
2018-10-11 |
2021-04-29 |
Amgen Inc |
Downstream processing of bispecific antibody constructs
|
JP2022512746A
(ja)
|
2018-10-19 |
2022-02-07 |
アンブルックス,インコーポレイテッド |
インターロイキン-10ポリペプチド複合体、その二量体、およびそれらの使用
|
MX2021005594A
(es)
|
2018-11-13 |
2021-10-22 |
Compass Therapeutics Llc |
Constructos multiespecificos de union contra moleculas de puntos de control y usos de los mismos.
|
EP3898614A1
(en)
|
2018-12-17 |
2021-10-27 |
Tolremo Therapeutics AG |
Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of cancer
|
KR20210113261A
(ko)
|
2019-01-04 |
2021-09-15 |
리졸브 테라퓨틱스, 엘엘씨 |
뉴클레아제 융합 단백질을 사용한 쇼그렌병의 치료
|
EP3914289A1
(en)
|
2019-01-23 |
2021-12-01 |
Massachusetts Institute of Technology |
Combination immunotherapy dosing regimen for immune checkpoint blockade
|
GB201901305D0
(en)
|
2019-01-30 |
2019-03-20 |
Immunocore Ltd |
Specific binding molecules
|
WO2020168017A1
(en)
|
2019-02-12 |
2020-08-20 |
Ambrx, Inc. |
Compositions containing, methods and uses of antibody-tlr agonist conjugates
|
AU2020242284A1
(en)
|
2019-03-19 |
2021-09-16 |
Fundació Privada Institut D'investigació Oncològica De Vall Hebron |
Combination therapy for the treatment of cancer
|
JP2022525781A
(ja)
|
2019-03-20 |
2022-05-19 |
マサチューセッツ インスティテュート オブ テクノロジー |
免疫細胞療法における両親媒性物質の使用およびそのための組成物
|
US20220259547A1
(en)
|
2019-06-13 |
2022-08-18 |
Amgeng Inc. |
Automated biomass-based perfusion control in the manufacturing of biologics
|
US11642409B2
(en)
|
2019-06-26 |
2023-05-09 |
Massachusetts Insttute of Technology |
Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
|
US20220324924A1
(en)
|
2019-07-08 |
2022-10-13 |
Amgen Inc. |
Multispecific transthyretin immunoglobulin fusions
|
US20220281966A1
(en)
|
2019-07-26 |
2022-09-08 |
Amgen Inc. |
Anti-il13 antigen binding proteins
|
GB201910900D0
(en)
|
2019-07-31 |
2019-09-11 |
Scancell Ltd |
Modified fc-regions to enhance functional affinity of antibodies and antigen binding fragments thereof
|
GB201910899D0
(en)
|
2019-07-31 |
2019-09-11 |
Scancell Ltd |
Binding members
|
US20210047425A1
(en)
|
2019-08-12 |
2021-02-18 |
Purinomia Biotech, Inc. |
Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells
|
AU2020328038A1
(en)
|
2019-08-13 |
2022-03-31 |
Amgen Inc. |
Interleukin-2 muteins for the expansion of T-regulatory cells
|
GB201912657D0
(en)
|
2019-09-03 |
2019-10-16 |
Scancell Ltd |
Binding members
|
GB201912882D0
(en)
|
2019-09-06 |
2019-10-23 |
Scancell Ltd |
Ssea-4 binding members
|
TW202124444A
(zh)
|
2019-09-16 |
2021-07-01 |
美商表面腫瘤學公司 |
抗cd39抗體組合物及方法
|
TW202128752A
(zh)
|
2019-09-25 |
2021-08-01 |
美商表面腫瘤學公司 |
抗il﹘27抗體及其用途
|
WO2021064142A1
(en)
|
2019-10-02 |
2021-04-08 |
Tolremo Therapeutics Ag |
Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer
|
WO2021064141A1
(en)
|
2019-10-02 |
2021-04-08 |
Tolremo Therapeutics Ag |
Inhibitors of dual specificity tyrosine phosphorylation regulated kinase 1b
|
WO2021074418A1
(en)
|
2019-10-16 |
2021-04-22 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Carbazole-type cullin ring ubiquitin ligase compounds and uses thereof
|
US20230124700A1
(en)
|
2019-10-16 |
2023-04-20 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Oxazole and thioazole-type cullin ring ubiquitin ligase compounds and uses thereof
|
CA3155202A1
(en)
|
2019-10-23 |
2021-04-29 |
Arthur M. Krieg |
Synthetic rig-i-like receptor agonists
|
WO2021080682A1
(en)
|
2019-10-24 |
2021-04-29 |
Massachusetts Institute Of Technology |
Monoclonal antibodies that bind human cd161 and uses thereof
|
JP2022554187A
(ja)
|
2019-10-24 |
2022-12-28 |
ミノトール セラピューティクス インコーポレイテッド |
キメラサイトカイン改変抗体およびその使用方法
|
WO2021097344A1
(en)
|
2019-11-13 |
2021-05-20 |
Amgen Inc. |
Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
|
US20230067910A1
(en)
|
2019-11-19 |
2023-03-02 |
Modag Gmbh |
Novel compounds for the diagnosis, treatment and prevention of diseases associated with the aggregation of alpha-synuclein
|
KR20220114595A
(ko)
|
2019-12-17 |
2022-08-17 |
암젠 인크 |
치료에서의 사용을 위한 이중 인터류킨-2/tnf 수용체 효현제
|
AU2021205877A1
(en)
|
2020-01-06 |
2022-06-09 |
Vaccinex, Inc. |
Anti-CCR8 antibodies and uses thereof
|
WO2021173889A1
(en)
|
2020-02-26 |
2021-09-02 |
Ambrx, Inc. |
Uses of anti-cd3 antibody folate bioconjugates
|
JP2023517595A
(ja)
|
2020-03-11 |
2023-04-26 |
アンブルックス,インコーポレイテッド |
インターロイキン-2ポリペプチド結合物およびその使用方法
|
WO2021188851A1
(en)
|
2020-03-19 |
2021-09-23 |
Amgen Inc. |
Antibodies against mucin 17 and uses thereof
|
WO2021221783A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
US20210338833A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Chimeric antigen receptor-targeting ligands and uses thereof
|
GB202101299D0
(en)
|
2020-06-09 |
2021-03-17 |
Avacta Life Sciences Ltd |
Diagnostic polypetides and methods
|
KR20230027294A
(ko)
|
2020-06-25 |
2023-02-27 |
톨레모 테라퓨틱스 아게 |
섬유성 질환의 치료, 개선 또는 예방을 위한 헤테로사이클릭 유도체, 약학 조성물 및 그들의 용도
|
CA3165342A1
(en)
|
2020-06-29 |
2022-01-06 |
James Arthur Posada |
Treatment of sjogren's syndrome with nuclease fusion proteins
|
EP3939578A1
(en)
|
2020-07-13 |
2022-01-19 |
Novaremed Ltd. |
Compounds for treatment or prevention of an infection resulting from a coronavirus and/or a coronavirus-induced disease
|
WO2022023292A2
(en)
|
2020-07-31 |
2022-02-03 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Corona virus spike protein-targeting antibodies and use thereof
|
US20230302150A1
(en)
|
2020-08-20 |
2023-09-28 |
Ambrx, Inc. |
Antibody-tlr agonist conjugates, methods and uses thereof
|
BR112023002195A2
(pt)
|
2020-08-26 |
2023-03-14 |
Scancell Ltd |
Ácido nucleico que codifica um polipeptídeo, vetor, peptídeo, e composição de vacina
|
EP3964497A1
(en)
|
2020-09-04 |
2022-03-09 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Substituted vicinal diamine compounds and their use in the treatment, amelioration or prevention of pain
|
EP4229081A1
(en)
|
2020-10-15 |
2023-08-23 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
|
EP4229037A2
(en)
|
2020-10-16 |
2023-08-23 |
CeMM - Forschungszentrum für Molekulare Medizin GmbH |
Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
|
WO2022087274A1
(en)
|
2020-10-21 |
2022-04-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies that neutralize type-i interferon (ifn) activity
|
IL302599A
(en)
|
2020-11-06 |
2023-07-01 |
Amgen Inc |
Bispecific molecules bind multi-target antigens of increased selectivity
|
AU2022224636A1
(en)
|
2021-02-19 |
2023-09-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies that neutralize sars-cov-2
|
KR20240004342A
(ko)
|
2021-04-03 |
2024-01-11 |
암브룩스, 인코포레이티드 |
항-her2 항체-약물 접합체 및 이의 용도
|
BR112023020538A2
(pt)
|
2021-04-07 |
2024-01-23 |
Tolremo Therapeutics Ag |
Derivados heterocíclicos, composições farmacêuticas e seus usos no tratamento ou na melhoria de câncer
|
CA3217865A1
(en)
|
2021-04-28 |
2022-11-03 |
Minotaur Therapeutics, Inc. |
Humanized chimeric bovine antibodies and methods of use
|
WO2022234102A1
(en)
|
2021-05-06 |
2022-11-10 |
Amgen Research (Munich) Gmbh |
Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
|
CA3215856A1
(en)
|
2021-05-07 |
2022-11-10 |
Alison O'neill |
Anti-il-27 antibodies and uses thereof
|
JP2024518178A
(ja)
|
2021-05-14 |
2024-04-25 |
クラリス・バイオセラピューティクス・インコーポレイテッド |
眼疾患の治療のための増殖因子の組成物
|
CA3230815A1
(en)
|
2021-09-03 |
2023-03-09 |
University Of Bern |
Compositions and methods for treating long ot syndrome
|
WO2023079493A1
(en)
|
2021-11-03 |
2023-05-11 |
Affimed Gmbh |
Bispecific cd16a binders
|
TW202334221A
(zh)
|
2021-11-03 |
2023-09-01 |
德商安富美德有限公司 |
雙特異性cd16a結合劑
|
US20230364031A1
(en)
|
2022-04-19 |
2023-11-16 |
Garth Cooper |
Treatment of brain copper disorders
|
WO2023203174A1
(en)
|
2022-04-20 |
2023-10-26 |
Proxygen Gmbh |
Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
|
TW202346368A
(zh)
|
2022-05-12 |
2023-12-01 |
德商安美基研究(慕尼黑)公司 |
具有增加的選擇性的多鏈多靶向性雙特異性抗原結合分子
|
WO2023230116A1
(en)
|
2022-05-25 |
2023-11-30 |
Surface Oncology, Inc. |
Use of anti-il-27 antibodies
|
US20240026001A1
(en)
|
2022-05-25 |
2024-01-25 |
Surface Oncology, Inc. |
Use of anti-il-27 antibodies
|
WO2024050526A1
(en)
|
2022-09-02 |
2024-03-07 |
Biomarin Pharmaceutical Inc. |
Compositions and methods for treating long qt syndrome
|
WO2024059675A2
(en)
|
2022-09-14 |
2024-03-21 |
Amgen Inc. |
Bispecific molecule stabilizing composition
|
WO2024076995A1
(en)
|
2022-10-03 |
2024-04-11 |
Insigna Inc. |
Compositions for non-surgical prevention of boar taint and aggressive behavior
|
WO2024089013A1
(en)
|
2022-10-25 |
2024-05-02 |
Peptomyc, S.L. |
Combination therapy for the treatment of cancer
|